Hematopoiesis News 10.35 September 10, 2019 | |
| |
TOP STORYAsymmetric Lysosome Inheritance Predicts Activation of Hematopoietic Stem Cells Researchers demonstrated that the cellular degradative machinery – including lysosomes, autophagosomes, mitophagosomes and the protein NUMB – can be asymmetrically inherited into hematopoietic-stem-cell daughter cells. [Nature] Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Insertion-site analyses revealed the multipotent nature of corrected HSCs and showed that the repopulation advantage of these cells was not due to genotoxic integrations of the therapeutic provirus. [Nat Med] Abstract Scientists showed that Stag2 deletion in hematopoietic stem and progenitor cells resulted in altered hematopoietic function, increased self-renewal, and impaired differentiation. [Cell Stem Cell] Abstract | Graphical Abstract Development of Hematopoietic Stem Cell-Engineered Invariant Natural Killer T Cell Therapy for Cancer HSC-invariant natural killer T (iNKT) cells closely resembled endogenous human iNKT cells, could deploy multiple mechanisms to attack tumor cells, and effectively suppressed tumor growth in vivo in multiple human tumor xenograft mouse models. [Cell Stem Cell] Abstract | Graphical Abstract Tracing the First Hematopoietic Stem Cell Generation in Human Embryo by Single-Cell RNA Sequencing Using single-cell RNA sequencing, investigators constructed the first genome-scale gene expression landscape covering the entire course of endothelial-to-HSC transition during human embryogenesis. [Cell Res] Full Article Human Genome-Edited Hematopoietic Stem Cells Phenotypically Correct Mucopolysaccharidosis Type I The authors present an efficient ex vivo genome editing approach using CRISPR-Cas9 that targeted the lysosomal enzyme iduronidase to the CCR5 safe harbor locus in human CD34+ hematopoietic stem and progenitor cells. [Nat Commun] Full Article Scientists showed that the mutant calreticulin (CALR) proteins could be detected in plasma. The phenotype of Calr del52 was transplantable, and Calr mutated hematopoietic cells had a slow-rising advantage over wild-type hematopoiesis. [Leukemia] Abstract CLINICAL RESEARCHA total of 122 patients were enrolled, with 19 patients in Part 1 and 75 patients in Part 2 receiving study drug. Improvements were seen with trilaciclib in neutrophil, RBC and lymphocyte measures. [Ann Oncol] Full Article The Ferroportin Q248H Mutation Protects from Anemia, But Not Malaria or Bacteremia Using data from cohorts including over 18,000 African children, investigators showed that the Q248H mutation was associated with modest protection against anemia, hemolysis, and iron deficiency, but they found little evidence of protection against severe malaria or bacteremia. [Sci Adv] Full Article Subscribe to one of our other 19 science newsletters such as Cord Blood News & Cell Therapy News. | |
| |
REVIEWSHLA haploidentical hematopoietic cell transplantation (haplo-HCT) using posttransplantation cyclophosphamide is an alternative strategy when a matched sibling donor (MSD) is not available. The authors performed a systematic review and meta-analysis to compare the outcomes of MSD vs haplo-HCT. [Blood Adv] Full Article Visit our reviews page to see a complete list of reviews in the hematopoiesis research field. | |
| |
INDUSTRY NEWSCellCentric Starts Dosing Patients in Blood Cancer Trial, Expanding Clinical Testing of CCS1477 CellCentric has expanded the clinical development programme of its novel anti-cancer drug CCS1477, a highly potent and specific small molecule inhibitor of p300/CBP. Dosing has commenced in a new study involving patients with multiple myeloma and will include those with acute myeloid leukemia and certain lymphomas. [Cellcentric] Press Release Selvita announced that the first patient enrolled in the Phase Ib study of company’s selective CDK8 inhibitor, SEL120, has received the first dose. SEL120 is being initially investigated in the treatment of patients with acute myeloid leukemia or high-risk myelodysplastic syndrome. [Selvita] Press Release BioXcel Therapeutics, Inc. announced that the FDA has granted Orphan Drug Designation for BXCL701, an investigational orally-available systemic innate immunity activator with dual mechanisms of action, for the treatment of AML. [BioXcel Therapeutics, Inc.] Press Release Celyad Successfully Doses First Patient with CYAD-01 Produced with OptimAb Manufacturing Process Celyad announced the successful administration of CYAD-01 produced with the OptimAb manufacturing process to a patient enrolled in cohort three of the Phase I DEPLETHINK trial. [Celyad] Press Release Trucode Launched to Advance Next-Generation Gene Editing Platform Trucode Gene Repair, Inc. announced that it is advancing its next-generation in vivo gene editing technology to correct mutations that cause sickle cell disease, cystic fibrosis, and other devastating genetic disorders. [Trucode Gene Repair, Inc.] Press Release Grant Funds Study on Cardiovascular Disease, Aging The National Institutes of Health’s Heart, Lung, and Blood Institute has recently awarded Dr. Christie Ballantyne a $6 million grant to begin research to better understand how clonal hematopoiesis of indeterminate potential contributes to atherosclerotic cardiovascular diseases. [Baylor College of Medicine] Press Release | |
| |
POLICY NEWSElsevier Investigates Hundreds of Peer Reviewers for Manipulating Citations The Dutch publisher Elsevier is investigating hundreds of researchers whom it suspects of deliberately manipulating the peer-review process to boost their own citation numbers. [Nature News] Editorial Google Bans Ads for Experimental Medical Treatments Google announced it would “prohibit advertising for unproven or experimental medical techniques such as most stem cell therapy, cellular (non-stem) therapy, and gene therapy.” [STAT News] Editorial
| |
EVENTSNEW Keystone Symposia: Stromal Cells in Immunity and Disease Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Faculty – Hematopoietic Biology and Malignancy (MD Anderson Cancer Center) Research Technologist (STEMCELL Technologies Inc.) Scientific Communications Coordinator (STEMCELL Technologies Inc.) Postdoctoral Fellowships – Hematopoietic Stem Cell Biology (University of Copenhagen) Postdoctoral Scholar – Autologous Stem Cell Therapy (Stanford University) Postdoctoral Scientist – Leukemia Microenvironment (Cedars-Sinai Medical Center) Postdoctoral Scholarship – Blood Cell Formation (Lund University) Research Lab Specialist – Tumor Microenvironment & Cell Behavior (University of Southern California) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Hematopoiesis News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|